Dermatology co Foamix teams with Switzerland's Galderma

Foamix Expands International Patent Protection for its Emollient Foam Platform

Foamix Extends Collaboration with Galderma

Foamix Ltd. and VIB Sign Co-Development Agreement for Innovative Topical Therapy for Psoriasis

Promius Pharma, LLC Launches Scytera™ (Coal Tar) Foam 2% for Treatment of Psoriasis

Foamix is Finalist for International 2008 SCRIP Award

Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis

Omnibus Survey:72% of Women Are Dissatisfied with Their Current Treament of Vaginal Infection

Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases

Foamix is a finalist for the Red Herring 100 Europe 2008 Award

BIRD invests $14m in 16 joint projects; English Hebrew

Foamix Announces New Foam Patent Approvals

Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis

Foamix Acquires Rights to Dual Chamber Aerosol Foam Technology

In-Pharma Technologist.com: Best Foam Forward

Foamix presents Innovative Intra-Vaginal Foam Delivery for Gynecology

Foamix Signs R&D Collaboration and License Agreement with Dr. Reddy’s for the Development and Commercialization of Psoriasis Foam

YNET: Collaboration with Warner Chilcott on gynecologic treatment (article in Hebrew)

Warner Chilcott and Foamix Collaborate on Gynecologic Foam Product

Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam

Globes: Foamix collaborates with Warner Chilcott on acne treatment

Warner Chilcott and Foamix Collaborate on Foam Product for the Treatment of Acne

Foamix and Taro Enter License Agreement for the Development and Commercialization of Foamix's PerFoam™ 1% for the Treatment of Head Lice

Globes: Foamix displays its wares

Foamix Announces New Waterless Foam Designed for Enhanced Skin Delivery - Useful for Steroids and Water Sensitive Drugs

Foamix’s Betamethasone Foam Demonstrates High Efficacy in Psoriasis Treatment and 85% Better Usability than Cream in Phase I/II Study

Foamix Names David Schuz as Senior Vice President, Intellectual Property

Foamix foam technology is featured in Ynet Health (Hebrew)

Foamix featured among finalists by AICC Eagle Star Awards for Deal of the Year

Foamix LTD is featured in Bioexecutive International, March 2006

Foamix CEO to Present “The Changing Face of Dermatology” at the Bio Business Forum at Bio International 2006 in Chicago, April 10, 2006

Foamix is featured in a news package about the thriving Israeli biotech scene, produced by FBC Media and broadcast globally on World Business

Live interview with Foamix Executive Director Dr. Stanley Hirsch on Duke and the Doctor, a radio program broadcast on 150 stations in the U.S. Dr. Hirsch discusses the benefits of foam and the Company’s plans for the future.

Foamix Receives Patents for OilGel™ In the U.S. and in Australia

Cosmeticsdesign.com: Foamix granted US patent for OilGel

LEO and Foamix to Develop Two New Medicated Foams for the Treatment of Psoriasis.

Foamix Granted Third U.S. Patent for OilGel™, In Development for Dermatological and Ophthalmic Applications.

Foamix Executive Director Dr. Stanley Hirsch to Present “Foamix - Innovative Delivery in Dermatology” at Bio-Europe 2005, November 8th at 8:30 a.m.

New Foam Product for the Treatment of Scabies: A Development Collaboration by Stiefel Laboratories, Inc. of the USA and Foamix Ltd. of Israel

Foamix Commences Phase II Study of TerbiFoam™ 2% Foam for the Treatment of Athlete’s Foot. Company Concurrently Conducts Phase II Study of Betamethasone 0.12% Emollient Foam for the Treatment of Psoriasis

Foamix to Showcase Emulsion-Based Cosmetic Foams at The Health and Beauty America (HBA) Conference in New York

Drug Topics: Are new lice treatments up to scratch?

Globes: Foamix lice treatment demonstrates 96% efficacy in Phase II/III study

Foamix’s PerFoam™ for the Treatment of Lice Demonstrates Safety and 96% Efficacy in Phase II/III Study

In-Pharma Technologist.com: Topical drug delivery gel patented by Foamix

Foamix Selected to Present at the Bio Business Forum at Bio International 2005 in Philadelphia in June

Israel 21C: Foam - the Israeli way to take the sting out of skin treatments

MarketWatch: Israel's Foamix eyes U.S. IPO in next 18 months

Globes article: Drug Delivery Technology co Foamix raising $5m

Foamix "Breaks the Ribbon" on New Facility

Foamix Unveils Unique Mupirocin Foam

Foamix Unveils Innovative Vaginal Foam

Frost & Sullivan alert : A new trend in dermatological drug delivery: foamy carriers

Phase II Psoriasis Study Approved

 
November 2006

Foam: The Future of Effective Cosmeceuticals

Dov Tamarkin, PhD, Meir Eini and Doron Friedman, PhD, Foamix Ltd.

Abstract: Foam products are emerging as the future vehicle for the delivery of cosmetic and cosmeceutical active agents. They can deliver active ingredients for a variety of skin conditions such as wrinkles, hyperpigmentation, acne and cellulite. This review will highlight several advantages of foam.

The paramount objective of cosmeceutical development is to create effective products based on state-of-the-art, active ingredients that are conveniently delivered. The vehicle used to deliver topical ingredients can influence the performance of such ingredients since it can affect the delivery of the active agent to the target site of action. The convenience of use is of course most important in assuring continuous treatment.

Properties such as these encourage or discourage the consistent use of a respective product. While semi-solid compositions such as creams, lotions, gels and ointments commonly are used by consumers, new forms are desired to achieve better control of the product’s application, to improve skin absorption and to maintain or bestow beneficial properties of cosmeceutical products to the skin.

Foam has become a prominent delivery system for topical active agents in dermatology. Its platform provides an easy-to-apply alternative to creams and ointments. Foam delivery is advantageous in that it easily spreads over large areas and it does not leave a greasy, sticky or oily film on the skin after application.

The use of foam in dermatology was first reported in 1977 by Woodward and Berry, who studied the therapeutic benefit of betamethasone benzoate in a hydroalcoholic quick-break foam in comparison with a corresponding semi-solid dosage form.1 Their study revealed high clinical efficacy in the treatment of psoriasis and excellent acceptability by patients. A comprehensive review on foam drug delivery in dermatology was reported in The American Journal of Drug Delivery in 2003.2 Recently, a number of dermatological foams have been launched in the United States and elsewhere with significant success, evident by high patient demand and remarkable sales records.

The successful acceptance of foam in dermatology is being followed by the emergence of cosmetic and cosmeceutical foams, which likely could constitute an important segment in the skin care market. In this article, the composition, properties and mechanisms of action of three types of cosmetic foam vehicles will be addressed. These include emollient foams based on o/w emulsions, w/o emulsion foams and oleaginous foams containing 70–90% oil.